Datapoint: AstraZeneca’s Saphnelo Cleared to Treat Lupus

The FDA on Monday approved AstraZeneca’s Saphnelo for the treatment of moderate to severe systemic lupus erythematosus (SLE), the most common form of the disease. The type I interferon receptor antagonist is the first approval for SLE since 2011, when GlaxoSmithKline’s Benlysta entered the market. While Saphnelo could pose a threat, Benlysta is highly advantaged in the SLE market basket. Its intravenous form holds covered or better status for 94% of all insured lives under the medical benefit vs. 65% of lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 8/2/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 8

Datapoint: Aetna-Allina Health Launch New Plan Designs in Minnesota

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 7

Datapoint: Oklahoma Medicaid Rolls Top 1M After Expansion

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 6

Datapoint: Blue Cross and Blue Shield of Montana Plots Medicare Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today